Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01391130 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01391130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01391130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2011
Completion date
February 28, 2017
Enrollment
110 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear cell renal cell carcinoma